Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06443866 · ClinicalTrials.gov registry record
I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer
A clinical trial of Thyroid Cancer and RAI-Refractory Thyroid Cancer, sponsored by Miami Cancer Research Center.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06443866: Recruiting study of Thyroid Cancer and RAI-Refractory Thyroid Cancer, sponsored by Miami Cancer Research Center.
NCT06443866 is a study of Thyroid Cancer and RAI-Refractory Thyroid Cancer that is actively recruiting participants, run by Miami Cancer Research Center. The registered enrollment target is 50 participants, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06443866, a study of Thyroid Cancer and RAI-Refractory Thyroid Cancer, is actively recruiting participants, sponsored by Miami Cancer Research Center.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to demonstrate the clinical utility of I-124 PET/CT imaging and dosimetry in patients with thyroid cancer including 1) Evaluation of extent (volume and pattern) of remnant tissue in post total thyroidectomy setting and distinction of nodal metastases vs remnant tissue for determination of indication for RAI ablation, 2) Evaluation of response to RAI remnant ablation, 3) Evaluation for suspected occult recurrent/metastatic disease, 4) Evaluation of extent of disease in patients with known metastatic disease and 5) Evaluation of RAI avidity of recurrent/metastatic thyroid cancer and response to treatment with thyroid kinase inhibitors (TKI). Patients who underwent total thyroidectomy for thyroid cancers are studied. Patients who are newly diagnosed, as well as those who have known or suspected to have recurrent or metastatic disease are eligible. Patients receiving TKI treatment are eligible for evaluation prior to and after the treatment. The patients who are considered for TKI/MAPK treatments undergo pre and post treatment with clinically determined oncoprotein/TKR therapeutic agent(s), including multi-TKI, selective BRAF, MEK, PI3K or ERK inhibitors or combination treatments.
Primary Outcome
Measurements: 1. Administered activity 2. Cumulated activity 3. Standard uptake value Calculations: 1\. Radiation absorbed dose to the target Correlations to be reported: 1. Administered activity vs absorbed dose 2. Absorbed dose vs response 3. SUV at 48h vs response
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Disease status detection
- DIAGNOSTIC_TEST Theranostic dosimetry
- DRUG I-124 PET/CT imaging
Study Locations (1)
Florida
- Miami Cancer Research Center - North Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2029-12 |
What NCT06443866 shows while recruiting
NCT06443866 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 3 interventions - of which Disease status detection is the first listed.
NCT06443866 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06443866 about?
NCT06443866 is a clinical study titled "I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer". The objective of this study is to demonstrate the clinical utility of I-124 PET/CT imaging and dosimetry in patients with thyroid cancer including 1) Evaluation of extent (volume and pattern) of remnant tissue in post total thyroidectomy setting and distinction of nodal metastases vs remnant tissue ...
What is the current status of trial NCT06443866?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2022-02-01. Estimated completion is 2029-12.
What conditions does trial NCT06443866 study?
This clinical trial studies the following conditions: Thyroid Cancer, RAI-Refractory Thyroid Cancer.
What interventions are being tested in trial NCT06443866?
The interventions under investigation include: Disease status detection (DIAGNOSTIC_TEST), Theranostic dosimetry (DIAGNOSTIC_TEST), I-124 PET/CT imaging (DRUG).
Who is sponsoring clinical trial NCT06443866?
This trial is sponsored by Miami Cancer Research Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06443866 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06443866's enrollment target sits among peer trials
50 25th of 46 higher than 22 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
RECRUITING
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI